Humacyte (HUMA) Cash & Current Investments (2020 - 2026)

Humacyte (HUMA) has 7 years of Cash & Current Investments data on file, last reported at $48.5 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $48.5 million, down 22.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 million (down 22.71% YoY), and the FY2025 annual result was $50.5 million, up 12.37% from the prior year.
• Cash & Current Investments fell to $48.5 million in Q1 2026 per HUMA's latest filing, from $50.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $206.2 million in Q1 2022 and troughed at $19.5 million in Q3 2025.
• A 5-year average of $96.4 million and a median of $93.6 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments soared 40094.6% in 2022, then plunged 79.4% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $151.9 million in 2022, then sank by 47.03% to $80.4 million in 2023, then tumbled by 44.14% to $44.9 million in 2024, then rose by 12.37% to $50.5 million in 2025, then dropped by 3.88% to $48.5 million in 2026.
• Business Quant data shows HUMA's Cash & Current Investments at $48.5 million in Q1 2026, $50.5 million in Q4 2025, and $19.5 million in Q3 2025.